RedHill Biopharma Ltd.
RDHLHealthcare|Drug Manufacturers - Specialty & Generic|IL
$0.43
+0.00 (+0.45%)
Cash / Share
$2.86
Financials
Financial Snapshot
Market Cap
$1.3M
Enterprise Value
-$2.7M
Revenue (TTM)
$6.8M
Net Income (TTM)
-$12.8M
Cash & Investments
$5.2M
Net Cash
$4.1M
Free Cash Flow (TTM)
-$11.2M
Operating CF (TTM)
-$11.2M
Debt/Equity
-1.00
Cash Runway & Burn Rate
Cash on Hand
$5.2M
Quarterly Burn
$2.8M
Monthly Burn
$930.8K
Est. Runway
~1.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $66.2M | $46.2M | $53.2M | $47.9M | $29.8M | $38.0M | $20.0M | $6.4M | $4.6M | $4.0M | $5.2M | |
| Operating Cash Flow | -$28.3M | -$44.8M | -$34.5M | -$40.7M | -$48.6M | -$65.0M | -$29.2M | -$35.8M | -$9.4M | -$9.7M | -$11.2M | |
| Free Cash Flow | -$28.4M | -$46.0M | -$34.5M | -$41.0M | -$102.4M | -$65.2M | -$29.4M | -$35.8M | -$9.4M | -$9.7M | -$11.2M | |
| Capital Expenditure | -$120.0K | -$1.2M | -$58.0K | -$203.0K | -$53.8M | -$115.0K | -$198.0K | -$11.0K | -$9.0K | -$5.0K | -$22.0K | |
| Financing Cash Flow | $36.0M | $25.7M | $41.8M | $35.5M | $84.4M | $73.5M | $11.5M | $21.4M | $8.4M | $7.3M | $8.9M |
R&D Spending
R&D (TTM)
$2.4M
R&D Intensity
35.1%
R&D Growth vs Prior
+18.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $101.0K | $4.0M | $8.4M | $6.3M | $64.4M | $85.8M | $61.8M | $6.5M | $8.0M | $286.0K | $6.8M | |
| R&D Expense | $25.2M | $33.0M | $24.9M | $17.4M | $16.5M | $29.5M | $7.3M | $3.5M | $1.6M | $2.0M | $2.4M | |
| R&D % of Revenue | 24991.1% | 822.8% | 297.4% | 276.9% | 25.6% | 34.4% | 11.8% | 54.0% | 19.7% | 707.3% | 35.1% | |
| SG&A | $5.4M | $20.0M | $20.0M | $29.8M | $74.7M | $88.0M | $64.0M | $31.0M | $15.5M | $6.2M | $11.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $101.0K | $4.0M | $8.4M | $6.3M | $64.4M | $85.8M | $61.8M | $6.5M | $8.0M | $286.0K | $6.8M | |
| Cost of Revenue | $30.5M | $2.1M | $2.8M | $2.3M | $36.9M | $49.4M | $33.3M | $3.5M | $3.2M | $0.00 | $2.5M | |
| Gross Profit | -$30.4M | $1.9M | $5.5M | $4.0M | $27.5M | $36.4M | $28.5M | $3.1M | $4.9M | $286.0K | $4.3M | |
| R&D | $25.2M | $33.0M | $24.9M | $17.4M | $16.5M | $29.5M | $7.3M | $3.5M | $1.6M | $2.0M | $2.4M | |
| SG&A | $5.4M | $20.0M | $20.0M | $29.8M | $74.7M | $88.0M | $64.0M | $31.0M | $15.5M | $6.2M | $11.7M | |
| Operating Income | -$30.5M | -$52.0M | -$39.3M | -$43.2M | -$63.7M | -$81.1M | -$42.8M | $12.6M | -$14.6M | -$7.9M | -$11.6M | |
| Interest Expense | $7.0K | $77.0K | $167.0K | $439.4K | $12.4M | $16.6M | $41.3M | $367.0K | $55.0K | $19.0K | $2.6M | |
| Pretax Income | -$29.4M | -$45.5M | -$38.8M | -$42.3M | -$76.2M | -$97.7M | -$71.7M | $23.9M | -$8.3M | -$8.1M | -$12.4M | |
| Net Income | -$29.4M | -$45.5M | -$38.8M | -$42.3M | -$76.2M | -$97.7M | -$71.7M | $23.9M | -$8.3M | -$429.0K | -$12.8M | |
| EPS (Diluted) | -1100.00 | -1300.00 | -850.00 | -700.00 | -1000.00 | -1000.00 | -600.00 | 46.00 | -7.00 | 0.00 | -3.00 | |
| EBITDA | -$30.5M | -$45.5M | -$38.7M | -$40.7M | -$55.0M | -$63.0M | -$22.2M | $26.3M | -$7.6M | -$7.7M | -$10.0M | |
| Shares Out. (M) | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 | 0.12 | 0.52 | 2.46 | 3.16 | 0.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.8M | $16.5M | $29.0M | $29.0M | $29.3M | $29.5M | $20.0M | $5.6M | $4.6M | $4.0M | $5.2M | |
| Short-Term Investments | $12.4M | $29.8M | $24.2M | $18.8M | $498.0K | $8.5M | $15.0K | $790.0K | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $67.8M | $51.7M | $56.8M | $53.2M | $70.5M | $89.2M | $85.9M | $16.1M | $11.9M | $6.5M | $8.6M | |
| Total Assets | $74.2M | $57.3M | $62.4M | $74.1M | $180.2M | $181.2M | $158.9M | $23.0M | $18.0M | $25.3M | $26.3M | |
| Total Current Liabilities | $5.4M | $11.8M | $10.4M | $10.6M | $73.2M | $81.5M | $197.5M | $19.2M | $22.2M | $19.2M | $25.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $81.4M | $83.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $11.5M | $12.3M | $11.2M | $14.1M | $166.4M | $172.3M | $207.3M | $21.0M | $22.7M | $21.1M | $27.4M | |
| Stockholders' Equity | $62.7M | $45.1M | $51.2M | $60.0M | $13.9M | $8.9M | -$48.4M | $2.1M | -$4.7M | $4.3M | -$1.1M | |
| Retained Earnings | -$89.6M | -$132.9M | -$169.1M | -$208.4M | -$280.3M | -$367.9M | -$433.9M | -$407.7M | -$414.8M | -$413.8M | -$419.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.3M | -$44.8M | -$34.5M | -$40.7M | -$48.6M | -$65.0M | -$29.2M | -$35.8M | -$9.4M | -$9.7M | -$11.2M | |
| Capital Expenditure | -$120.0K | -$1.2M | -$58.0K | -$203.0K | -$53.8M | -$115.0K | -$198.0K | -$11.0K | -$9.0K | -$5.0K | -$22.0K | |
| Free Cash Flow | -$28.4M | -$46.0M | -$34.5M | -$41.0M | -$102.4M | -$65.2M | -$29.4M | -$35.8M | -$9.4M | -$9.7M | -$11.2M | |
| Investing Cash Flow | $24.5M | -$18.6M | $5.4M | $5.2M | -$35.6M | -$8.1M | $8.3M | $4.0K | -$9.0K | $1.7M | $364.0K | |
| Financing Cash Flow | $36.0M | $25.7M | $41.8M | $35.5M | $84.4M | $73.5M | $11.5M | $21.4M | $8.4M | $7.3M | $8.9M | |
| Issuance of Stock | $35.8M | $22.2M | $41.9M | $36.3M | $23.9M | $78.5M | $23.8M | $14.0M | $8.3M | $7.8M | $5.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$796.0K | $76.5M | -$1.7M | -$1.5M | -$1.2M | -$636.0K | -$447.0K | $0.00 | |
| Stock Based Comp. | $1.7M | $2.2M | $2.7M | $3.0M | $4.2M | $10.2M | $5.7M | $1.6M | $665.0K | $457.0K | $819.0K | |
| Net Change in Cash | $32.3M | -$37.3M | $12.6M | $18.0K | $272.0K | $179.0K | -$9.5M | -$14.4M | -$952.0K | -$646.0K | $1.2M |
Dilution Tracker
Shares outstanding grew 4236.3% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+4236.3%
Stock Issuance (TTM)
$5.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 | 0.12 | 0.52 | 2.46 | 3.16 | 0.00 | |
| Change vs Prior % | — | 37.1% | 30.9% | 28.4% | 22.7% | 27.7% | 33.1% | 318.4% | 375.6% | 28.2% | -100.0% | |
| Stock Issuance | $35.8M | $22.2M | $41.9M | $36.3M | $23.9M | $78.5M | $23.8M | $14.0M | $8.3M | $7.8M | $5.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.7M | $2.2M | $2.7M | $3.0M | $4.2M | $10.2M | $5.7M | $1.6M | $665.0K | $457.0K | $819.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -30140.6% | 46.9% | 66.1% | 64.1% | 42.7% | 42.4% | 46.1% | 47.0% | 60.3% | 100.0% | 63.3% | |
| Operating Margin % | -30240.6% | -1297.0% | -470.5% | -686.7% | -99.0% | -94.6% | -69.3% | 193.4% | -181.7% | -2765.4% | -170.1% | |
| Net Margin % | -29079.2% | -1136.6% | -464.4% | -672.5% | -118.4% | -114.0% | -116.0% | 366.2% | -102.8% | -150.0% | -188.2% | |
| EBITDA Margin % | -30197.0% | -1134.6% | -463.3% | -647.0% | -85.4% | -73.5% | -35.9% | 402.3% | -94.4% | -2675.5% | -146.5% | |
| FCF Margin % | -28097.0% | -1146.7% | -412.9% | -651.0% | -159.0% | -76.0% | -47.5% | -548.7% | -116.6% | -3376.2% | -164.2% | |
| ROE % | -46.8% | -101.1% | -75.8% | -70.5% | -549.4% | -1101.3% | 148.1% | 1155.9% | 176.6% | -10.1% | -438.2% | |
| ROA % | -39.6% | -79.4% | -62.2% | -57.1% | -42.3% | -53.9% | -45.1% | 103.8% | -45.8% | -1.7% | -31.1% | |
| ROIC % | -44.4% | -114.2% | -75.6% | -67.2% | -58.6% | -80.1% | -55.2% | 279.3% | 381.8% | -125.7% | -680.3% | |
| R&D / Revenue % | 24991.1% | 822.8% | 297.4% | 276.9% | 25.6% | 34.4% | 11.8% | 54.0% | 19.7% | 707.3% | 35.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3266.7% | 3867.3% | 108.6% | -24.7% | 923.0% | 33.2% | -27.9% | -89.4% | 23.2% | -96.4% | |
| Gross Profit | -38.4% | 106.2% | 193.6% | -27.0% | 581.2% | 32.3% | -21.7% | -89.2% | 58.0% | -94.1% | |
| Operating Income | -38.8% | -70.2% | 24.3% | -9.8% | -47.4% | -27.4% | 47.2% | 129.5% | -215.7% | 45.9% | |
| Net Income | -39.3% | -55.1% | 14.8% | -9.0% | -80.1% | -28.3% | 26.7% | 133.4% | -134.6% | 94.8% | |
| EPS (Diluted) | -15.8% | -18.2% | 34.6% | 17.6% | -42.9% | 0.0% | 40.0% | 107.7% | -115.2% | 100.0% | |
| Operating Cash Flow | -58.5% | -58.4% | 23.0% | -18.2% | -19.2% | -33.9% | 55.1% | -22.7% | 73.8% | -3.0% | |
| Free Cash Flow | -45.8% | -61.9% | 24.9% | -18.6% | -149.9% | 36.3% | 54.9% | -21.9% | 73.8% | -3.0% | |
| R&D Expense | 42.0% | 30.6% | -24.6% | -29.9% | -5.3% | 78.9% | -75.3% | -51.5% | -55.0% | 27.4% | |
| SG&A Expense | 30.7% | 270.9% | -0.2% | 49.1% | 150.4% | 17.9% | -27.2% | -51.6% | -49.9% | -60.2% | |
| Total Assets | 11.0% | -22.7% | 8.8% | 18.7% | 143.2% | 0.5% | -12.3% | -85.5% | -21.7% | 40.5% | |
| Book Value / Share | -10.0% | -47.7% | -13.3% | -8.7% | -81.2% | -49.9% | -509.7% | 101.0% | -147.6% | 171.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 2177.9% | 1.0% | 39.7% | -99.0% | -69.7% | 200.6% | |
| Diluted Shares | 15.3% | 37.1% | 30.9% | 28.4% | 22.7% | 27.7% | 33.1% | 318.4% | 375.6% | 28.2% |
Valuation
P/E (TTM)At Loss
P/S0.66
10Y Low / Med / High0.28 / 11.38 / 2661.81
P/B-0.72
10Y Low / Med / High0.76 / 6.01 / 42.46
EV/EBITDA0.45
EV/Revenue-1.34
10Y Low / Med / High1.23 / 10.04 / 2129.28
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$2.86
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -9.51 | -3.95 | -6.53 | -8.67 | -8.08 | -2.58 | -0.23 | 0.79 | -0.89 | -7.58 | -0.43 | |
| P/S Ratio | 2661.81 | 45.30 | 30.70 | 57.30 | 9.15 | 2.80 | 0.28 | 2.90 | 1.90 | 11.38 | 0.66 | |
| P/B Ratio | 4.29 | 4.03 | 5.01 | 6.01 | 42.46 | 27.05 | -0.36 | 9.14 | -3.27 | 0.76 | -0.72 | |
| EV/EBITDA | -7.05 | -3.63 | -5.88 | -8.24 | -11.76 | -4.73 | -5.41 | 0.55 | -1.45 | -0.05 | 0.45 | |
| EV/Revenue | 2129.28 | 41.19 | 27.23 | 53.29 | 10.04 | 3.48 | 1.94 | 2.22 | 1.37 | 1.23 | -1.34 |
Analyst Estimates & Quality
Altman Z-Score
-24.13
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 |
|---|---|
| Revenue | $50.6M |
| Net Income | $0.00 |
| EPS | $0.00 |
| # Analysts (EPS) | 0 |
Revenue Segments
By Product
| Segment | 2024 |
|---|---|
| Movantik | $900.0K |